1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta D, Morales-Cacho L, Álvarez R, Sun P, Rosas-Perez B, Barrero R, Jiménez-Parrado S, López-García A, San Roman M, López-Gil JC, Drosten M, Sainz B Jr, Musteanu M, Caleiras E, Dusetti N, Poli V, Sánchez-Bueno F, Guerra C, Barbacid M.

    A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 122(49): .

    [doi:10.1073/pnas.2523039122]

  • Salazar J, Arranz MJ, Martin-Broto J, Serra M, Palmerini E, Martínez-García J, Juan-Ribelles A, Andion M, Martinez-Trufero J, Gutiérrez G, Echebarria-Barona A, Vaz-Salgado MA, Regueiro A, Alvarez R, Valverde C, Luna P, Blay P, Sebio A.

    VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

    PHARMACEUTICALS . 18(12): .

    [doi:10.3390/ph18121855]

  • Rabadan R, Filip I, Balsells J, López de Maturana E, Langtry A, Alonso L, Sabroso-Lasa S, Moreno-Oya A, Gómez-Rubio P, Molina-Montes E, Márquez M, Milne R, Alfaro A, Lobato T, Estudillo L, Real FX, Malats N, Scarpa A, Lawlor R, Beghelli S, Alvarez-Gallego R, Cubillo A, Hidalgo M, Peinado P, Salas I, Rodríguez Pascual J, Carrato A, Earl J, Caminoa A, Guillén-Ponce C, Rodríguez-Garrote M, Longo-Muñoz F, Ferreiro R, Pachón V, Vaz MÁ, Muñoz M, Iglesias M, Ilzarbe L, Álvarez-Urturi C, Bessa X, Bory F, Márquez L, Poves I, Burdío F, Grande L, Gimeno J, Molero X, Guarner L, Balcells J, Salcedo M, Merino X, Michalski CW, Esposito I, Kleeff J, Kong B, Mota C, Löhr MJ, Huang J, Verbeke C, Ye W, Yu J, Loinaz C, Perea J, Rodríguez-Peralto JL, Teijo A, Peláez P, Farré A, Mora J, Martín M, Artigas V, Guarner C, Sancho FJ, Concepción M, Ramón Y Cajal T, Szafranska J, O'Rorke M, Murray L, Cantwell M, Barberà VM, Gallego J, Tardón A, Barneo L, Rodriguez-Suarez MM, Domínguez-Muñoz E, Pazos Y, Lozano A, Luaces M, Blanco-Antona F, Sayagués Manzano JM, Gutiérrez Troncoso ML, Orfao de Matos A, Muñoz-Bellvís L, Gress TM, Buchholz M, Neesse A, Greenhalf W, Costello E, Crnogorac-Jurcevic T, Kocher HM, Bhattacharya S, Abraham AT, Ennis D, Dowe T, Radon T, O'Driscoll D, Sharp L.

    Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.

    NATURE COMMUNICATIONS . 16(1): 10769-10769.

    [doi:10.1038/s41467-025-65811-y]

  • Soler G, Grávalos C, Rivera F, Safont MJ, Virgili AC, Valladares-Ayerbes M, Ferreiro-Monteagudo R, Ortiz-Morales MJ, Polo-Marques E, Kornusova-Bersheva I, Soustre E, Yao W, Élez E.

    Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial.

    CLINICAL & TRANSLATIONAL ONCOLOGY . 27(11): 4203-4213.

    [doi:10.1007/s12094-025-03907-z]

  • Van Laethem JL, Geboes K, Borbath I, Macarulla Mercade T, Lambert A, Cassier P, Prenen H, Mitry E, Blanc JF, Pilla L, Feliu J, Rodriguez Garrote M, Pazo-Cid RA, Gallego I, Smith KE, Nordbladh K, Jimenez DG, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Beatty GL, O'Reilly EM.

    CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.

    CELL REPORTS MEDICINE . 6(10): 102407-102407.

    [doi:10.1016/j.xcrm.2025.102407]

  • Vaz-Salgado MA, Sepulveda JM, Earl J, Gutierrez J, Ruano Y, Pian H, Cantero D, Segura-Collar B, Gargini R, Hernández-Laín A.

    Oligodendrogliomas, cyclin pathway after the introduction of the molecular 2021 World Health Organization (WHO) criteria.

    Brain Communications . 7(5): .

    [doi:10.1093/braincomms/fcaf380]

  • Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T, Broto JM.

    Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

    JOURNAL OF CLINICAL ONCOLOGY . 43(28): 3113-3122.

    [doi:10.1200/JCO-25-00210]

  • Vaz-Salgado MA, Valverde-Morales C, Alvarez R, Asencio JM, Collado E, de Alava E, Diaz Beveridge R, Gómez-Mateo MC, Gracia Alegria I, Marquina G, Martin Broto J, Martínez-Trufero J, Narváez JA, Redondo A, Sebio A, Verges R, Viñals JM, García Del Muro X.

    Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

    Cancers . 17(19): .

    [doi:10.3390/cancers17193158]

  • Abal-Sanisidro M, Palencia-Campos A, Ruiz-Cañas L, García-Fernández J, Cañada-García L, Batres-Ramos S, López-López R, Moreno R, Martín-Pastor M, Sainz B Jr, de la Fuente M.

    Biocompatible self-illuminating sphingomyelin nanosystems for photodynamic-based cancer therapy.

    J CONTROL RELEASE . 385: 113982-113982.

    [doi:10.1016/j.jconrel.2025.113982]

  • Avendaño-Ortiz J, Tribaldo A, Ballestero L, Gómez LA, Gracia I, Rodríguez JF, Ramírez NB, Bodoque-Villar R, Vaz-Salgado MÁ, Del Campo R, Redondo-Calvo FJ.

    Antimicrobial Activity of Natural Extracts Against Catheter-Colonizing Methicillin-Resistant Staphylococcus aureus Clinical Isolates.

    Biomedicines . 13(9): .

    [doi:10.3390/biomedicines13092150]

  • Martelli V, Vidal J, Gibert J, Fernández-Rodríguez MC, Linares J, García-Alfonso P, Páez D, Alonso V, Gomez-España MA, Guix M, Santos C, Duran G, Élez E, Garcia-Carbonero R, Ferreiro R, Pineda E, Sastre J, Cano MT, Manzano JL, Losa F, Aranda E, Rivera F, Sibilio A, Toledo R, Tabernero J, Salazar R, Bellosillo B, Montagut C.

    Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.

    ESMO open . 10(9): 105760-105760.

    [doi:10.1016/j.esmoop.2025.105760]

  • Parejo-Alonso B, Barneda D, Trabulo SMD, Courtois S, Compte-Sancerni S, Zurkovic J, Ruiz-Cañas L, Zheng Q, Tang J, Gaida MM, Schmitz U, Irun P, Penin-Peyta L, Crusz SM, Jagušt P, Espiau-Romera P, Royo-García A, Gordo-Ortiz A, Yuneva M, Lin ML, Huang S, Yang MH, Lanas A, Sainz B Jr, Thiele C, Heeschen C, Sancho P.

    PPARd Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer.

    CANCER RESEARCH . 85(17): 3275-3291.

    [doi:10.1158/0008-5472.CAN-24-3475]

  • Melones-Herrero J, Aguilar-Rico F, Matesanz AI, Calés C, Sánchez-Pérez I, Quiroga AG.

    Antiproliferative activity in breast cancer cells of PtL(2): A steroid-thiosemicarbazone platinum(II) complex.

    JOURNAL OF INORGANIC BIOCHEMISTRY . 270: 112923-112923.

    [doi:10.1016/j.jinorgbio.2025.112923]

  • Cave DD, Di Domenico A, Fantuz M, Ciotola M, Mangini M, Buonaiuto S, Corrado B, Corona M, Saracino F, Andolfi G, Di Biase I, Cucciardi A, Carrer A, Sainz B Jr, Pirozzi T, Re DL, Colonna V, Minchiotti G, De Luca AC, Lonardo E.

    TGF-ß1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis.

    CELL DEATH & DISEASE . 16(1): 592-592.

    [doi:10.1038/s41419-025-07859-8]

  • Vaz-Salgado MA, Sepulveda JM, Earl J, Gutierrez J, Ruano Y, Pian H, Cantero D, Hernández-Lain A.

    Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.

    Brain Communications . 7(4): .

    [doi:10.1093/braincomms/fcaf265]

  • Earl J, Kataki A, Canzian F, Costello E, Campa D, Greenhalf W.

    Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancreatic cancer: The arguments for and against.

    Seminars in cancer biology . 113: 1-8.

    [doi:10.1016/j.semcancer.2025.05.001]

  • He J, Alhamwe BA, Sabroso S, Carrato A, Hidalgo M, Molero X, Iglesias M, Perea J, Farré A, Tardón A, Dominguez-Muñoz E, Barberà V, Muñoz-Bellvís L, Löhr M, Greenhalf W, O'Rorke M, Gress T, Crnogorac-Jurcevic T, Gayà A, Langtry A, Kleeff J, Lawlor R, Real FX, Renz H, Malats N.

    Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk.

    INTERNATIONAL JOURNAL OF CANCER . 157(3): 468-479.

    [doi:10.1002/ijc.35397]

  • Alsina M, Villacampa G, de Andrea C, Vivancos A, Ponz-Sarvise M, Arrazubi V, Jimenez-Fonseca P, Diez M, Sanz-Garcia E, Martínez E, Guardeño R, Calvo M, Bugés C, Longo F, Navarro V, García-Galea E, Gros A, Ochoa MC, Lopez-Janeiro A, Sanchez-Gregorio S, Herrero C, Labiano I, Vila-Casadesús M, López D, Alexandru R, Muñoz S, Tabernero J, Melero I.

    Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.

    CLINICAL CANCER RESEARCH . 31(14): 2890-2898.

    [doi:10.1158/1078-0432.CCR-25-0369]